Polymorphisms in MHC class II molecules, in particular around β-chain position-57 (β57), afford susceptibility/resistance to multiple autoimmune diseases, including type 1 diabetes, through obscure mechanisms. Here, we show that the antidiabetogenic MHC class II molecule I-A b affords diabetes resistance by promoting the differentiation of MHC-promiscuous autoreactive CD4
+ T cells into diseasesuppressing natural regulatory T cells, in a β56-67-regulated manner. We compared the tolerogenic and antidiabetogenic properties of T he HLA gene region on human chromosome 6 accounts for >50% of the genetic risk for autoimmune diseases (including T1D) (1) . Genes encoding HLA-DQ and -DR and their murine counterparts (I-A and I-E, respectively) (2), as well as class I genes (3, 4) , play key roles, albeit through poorly understood mechanisms. Human T1D is primarily associated with HLA-DQB1. Alleles encoding DQβ chains with Ser, Ala, or Val at position 57 provide risk, whereas those encoding DQβ chains with Asp at this position afford protection in most, though not all, populations (5) (6) (7) . The nonobese diabetic (NOD) mouse is homozygous for a unique H-2 haplotype (H-2 g7 ). This haplotype carries a nonproductive I-Eα gene and encodes an I-Aα d /I-Aβ g7 heterodimer in which the Pro and Asp found at positions 56 and 57 in most I-Aβ chains are replaced by His and Ser, respectively (5, 6) . Early studies of NOD mice expressing non-NOD MHC haplotypes or MHC class II transgenes have proven that class II molecules play a direct role. Evidence for enhanced central T-cell tolerance and T-cell-mediated immunoregulation or immune deviation (8) (9) (10) (11) (12) (13) has been provided. However, a unifying conclusion could not be drawn from these individually reported mechanisms, as they could not explain, on their own, MHC class II-mediated resistance to polyclonal T-cell-mediated autoimmune diabetes.
We previously reported that thymocytes carrying a diabetogenic I-A (17) . Interestingly, the I-A molecules capable of deleting 4.1-thymocytes display a conserved stretch of amino acids at β-chain positions 56-67, which differ from those in I-Aβ g7 (17) . On the basis of these and other observations (18, 19) , we hypothesized that protective class II molecules afford T1D resistance by deleting "4.1-like" (MHC-promiscuous and diabetogenic) CD4
+ T cells, and that I-Aβ-chain residues 56-67 play a critical role.
The present study was thus initiated to investigate if the MHC class II-induced resistance to T1D in non-TCR transgenic NOD mice can be accounted for by central tolerance of 4.1-like CD4 + T cells, if this phenotype is triggered by thymic epithelial cells or dendritic cells (DCs), and if the polymorphic residues at and around the T1D-associated β-chain position 57 play a key role and, if so, how. This investigation was done by assessing the diabetes resistance of NOD and 4.1-NOD mice expressing wild-type and modified I-A b transgenes under the control of K14 and CD11c promoters, and following the fate and function of 4.1-thymocytes. Our data demonstrate that antidiabetogenic MHC class II molecules afford T1D resistance both by deleting and skewing the development of MHC-promiscuous autoreactive thymocytes into autoregulatory CD4
+ T-cells, and that these two phenotypes are triggered by DCs without any contribution from thymic epithelial cells. Unexpectedly, we find that replacement of I-Aβ b residues 56-67 by their I-Aβ g7 -derived counterparts abrogates the ability of I-A b to delete 4.1-thymocytes, but not its ability to promote the development of these thymocytes into antidiabetogenic regulatory T cells (Tregs). We propose that polymorphisms proximal to β-chain position 57 contribute to the antidiabetogenic effects of protective MHC class II alleles by enhancing the avidity with which these molecules are recognized by thymocytes expressing MHCpromiscuous autoreactive TCRs. Analyses of splenic CD19 + and CD11b + cells confirmed that transgene expression was restricted to DCs (Fig.  S2C ). Transgene expression did not cause a reduction in either the levels of endogenous I-A g7 on DCs (Fig. S2D ) or in the ability of antigen-pulsed DCs to support the activation of I-A g7 -restricted BDC2.5 CD4
+ T cells (Fig. S2F) . Furthermore, transgene expression did not reduce the percentages of B cells in the peripheral lymphoid organs (Fig. S2G) , which caused a reduction in the incidence of diabetes in NOD mice expressing high levels of an I-A g7 transgene in all professional APC types (23) .
Thus, the DCs of NOD.CD11cP-I-Aαβ b , NOD.CD11cP-I-Aαβ b-g7 , and NOD.CD11cP-I-Aβ b mice express comparable levels of transgenic MHC class II and this does not interfere with the expression of diabetogenic I-A g7 , the DCs' antigenpresentation capacity, or B-cell development. 
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down-regulation of the transgenic and total TCR levels ( proliferated significantly less and secreted lower levels of IFN-γ when challenged with NOD islet cells (but not anti-CD3 mAb) than those isolated from 4.1-NOD mice (Fig. 2E ). In addition, these cells could not transfer disease to NOD.scid hosts (Fig.  2F ), indicating that DC-specific expression of I-A b affords diabetes protection to 4.1-TCR transgenic mice, at least in part, by tolerizing 4.1-CD4
+ T cells during their development.
DC-Specific Expression of I-A b-g7 Affords Diabetes Resistance to 4.1-CD4
+ T-Cell-Induced Diabetes Without Inducing Deletional Tolerance or Anergy. Surprisingly, 4.1-NOD.CD11cP-I-A b-g7 mice did not exhibit any of these phenotypes (Fig. 2 A-E and Fig. S4 ), despite the fact that they displayed similar resistance to diabetes than 4.1-NOD.CD11P-I-A b mice ( Fig. 1 E and F) . In fact, the splenic CD4 .Rag2 −/− mice are resistant to diabetes (Fig. 1F) , we conclude that DC-specific expression of I-A b-g7 affords diabetes resistance by a mechanism dissociated from central tolerance of 4.1-like CD4 + cells. That is, I-Aβ residues 56-67 are important for mediating central tolerance of 4.1-like CD4 + cells, but are dispensable for diabetes resistance. (Fig. 3A) . Helios staining confirmed that these differences were largely attributable to thymic derived Foxp3 + Tregs (Fig. 3 B and C) . (Fig. 3E) .
Given that both RAG2 + and RAG2 
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transfer of diabetes by splenic T-cells from wild-type NOD mice (Fig. 3G) (Fig. 3H) , albeit not in the peripheral T-cell subsets other than the islet-infiltrating one (enriched for autoreactive clonotypes), presumably because of the significantly reduced frequency of 4.1-like TCRs in non-TCR transgenic mice. Furthermore, Tregs purified from the pooled pancreatic-draining lymph nodes (PLNs) (but not spleen) of both NOD.CD11cP-I-A(α)β b and NOD.CD11cP-I-Aαβ b-g7 mice exhibited different TCR use than those isolated from the PLNs of NOD mice, as determined using a V family-specific nested-PCR approach (29) (Fig. S5 A and B) . These separate lines of evidence suggested that the Foxp3
+ Treg subset developing in non-TCR transgenic NOD.CD11cP-I-A(α)β b and NOD.CD11cP-I-Aαβ b-g7 mice is also enriched for autoreactive Treg cell specificities, leading to enhanced recruitment and retention in their PLNs. To substantiate this further, we compared the accumulation of splenic carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled Tregs from NOD.CD11cP-I-Aβ b and NOD donors (labeled with low and high CFSE concentrations, respectively, and pooled at a 1:1 ratio) into the mesenteric lymph nodes (MLNs) and PLNs of wild-type NOD hosts. As shown in Fig. S5C , NOD.CD11cP-I-Aβ b -derived Tregs accumulated in the PLNs more efficiently than NOD-derived Tregs, supporting the idea that I-A b expression promotes the development of islet-antigen autoreactive Tregs but is dispensable for enhanced recruitment of these T cells into the PLNs.
Furthermore, in vivo experiments showed that Tregs from NOD.CD11cP-I-A(α)β b and NOD.CD11cP-I-Aαβ b-g7 mice were significantly more suppressive in the NOD.scid diabetes transfer model than Tregs isolated from NOD mice (Fig. 3I) . In agreement with this, the PLNs of both NOD.CD11cP-I-A(α)β b and NOD.CD11cP-I-Aαβ b-g7 mice were significantly less able to support the proliferation of CFSE-labeled 8.3-CD8 + T cells than the PLNs of NOD mice (Fig. 4) (n = 5) mice were injected into 6-wk-old NOD.scid female mice, followed by an infusion of splenic T-cells (2 × 10 7 ) from prediabetic NOD females (7-to 9-wk-old). Diabetes was monitored for at least 100 d. P values were calculated using Mann-Whitney U test (A, C, F, H), two-way ANOVA (D), logrank test (E, G), and χ 2 analysis (I). + CD25 + splenocytes from both TCR transgenic and non-TCR transgenic mice expressing either I-A b or I-A b-g7 had superior antidiabetogenic activity than those derived from their non-I-A transgenic counterparts. Although a control CD11c promoter-driven I-A g7 transgenic mouse was not made (it would not have been possible to differentiate transgenic from endogenous I-A g7 , hence assess levels of transgene expression), the outcome of these experiments cannot be accounted for by systemic I-A g7 overexpression. Unlike the case in NOD mice expressing high levels of an I-A g7 transgene in all professional APC types, which displayed significant reductions in the percentages of B-cells and a reduced incidence of diabetes (23), the transgenic mice described herein express normal levels of total I-A g7 and relatively low levels of the transgenes only on CD11c + cells, and have normal numbers of B-cells. Nevertheless, we cannot completely rule out effects of transgene expression on some of the read-outs.
Collectively, these data demonstrate that DCs play a central role in the antidiabetogenic activity of at least certain protective class II alleles; that these molecules afford T1D resistance by promoting the deletion of MHC-promiscuous autoreactive thymocytes and their differentiation into autoregulatory T-cells; and that residues around β-chain position 57 control the magnitude of this process, presumably by modifying the avidity of the TCR-MHC interaction (Fig. S6) . Because the MHC promiscuity of the 4.1-TCR is peptide-dependent (16) and residues 57, 61, and 67 in I-A g7 interact with bound peptides (30) , the I-A b-g7 replacement likely resulted in a conformational change in I-A b capable of altering the repertoire of bound peptides and the affinity with which it is engaged by the 4.1-TCR. Additionally, these results demonstrate that β-chain polymorphisms residing outside of positions 56-67, such as residue 26, lying in the P4 pocket (31) , also play a role in the antidiabetogenic activity of protective MHC class II molecules.
Whatever the structural underpinnings, these results support the hypothesis that MHC-promiscuous autoreactive TCRs like the 4.1-TCR play a key role in the development of T1D, and that antidiabetogenic MHC class II polymorphisms harness these TCRs intrinsic MHC-promiscuity to generate autoregulatory T cells. We note that the MHC-promiscuous nature (i.e., the ability to recognize different MHC molecules) of the 4.1-TCR has also been documented for diabetogenic MHC class I-restricted TCRs (32) and a human encephalitogenic TCR (33). Although we cannot exclude the possibility that protective MHC class II molecules select for Tregs that afford increased diabetes protection by competing with effectors of the same antigenic specificity, we think that this phenomenon linking MHC promiscuity with pathogenic autoreactivity (15) is more related to how pathogenic autoreactive TCRs engage cognate pMHC than to the nature of their autoantigenic targets. Several autoreactive TCRs have been noted to bind cognate pMHCs with a different topology than foreign antigen-specific TCRs, or to recognize peptides that only partially occupy the MHC peptide-binding groove (34, 35) . Polymorphic MHC residues on protective MHC class II may compensate for the paucity of molecular contacts between TCR and peptide and disease-promoting MHC. This interpretation would help explain how a structurally diverse repertoire of class II molecules, binding a diverse array of peptides, can afford dominant resistance to an autoimmune disease, the development of which requires expression of a completely different class II molecule, I-A g7 , and which is effected by a diverse repertoire of autoreactive T-cell specificities. Furthermore, this hypothesis accords with the fact that the MHC promiscuity of the 4.1-TCR and the DQB1-linked resistance to murine and human T1D both map to residues around β-chain position 57 (5, 6, 17) .
Materials and Methods
Mice. Laufer, University of Pennsylvania, Philadelphia, PA) were backcrossed to NOD mice for at least 10 generations.
Peptides. The peptides NRP-A7 (KYNKANAFL) (36), and 2.5mimetope (37) were purchased from Mimotopes Pty Ltd.
Flow Cytometry. Cell suspensions were stained with Abs or streptavidin diluted 1:100 in FACS buffer [PBS containing 1% (vol/vol) FBS and 0.05% NaN 3 ], washed, fixed in 1% (vol/vol) PFA in PBS and analyzed by flow cytometry. Intracellular staining of Foxp3, Helios, and Nur77 were performed using the intracellular staining buffer kit from eBioscience. AnnexinV/Propidium iodide staining was performed according to the manufacturer's recommendations.
In Vivo CFSE Dilution. Pure CFSE-labeled T-cells (5 × 10 6 ) were injected intravenously into NOD or transgenic hosts, and spleens, MLNs, and PLNs were collected for flow cytometry at day 7 postinjection. The cultures were examined for thymidine incorporation and cytokine secretion. For polyclonal T-cell stimulation, we used anti-CD3/CD28 beads.
In Vitro Treg Suppression Assay. CD4 + CD25 + or CD4 + CD25 -T-cells were activated with plate-bound anti-CD3 mAb (3 μg/mL) and IL-2 (18 ng/mL) and cocultured at different ratios with responder 8.3-CD8 + T-cells (2 × 10 4 ) and γ-irradiated NOD splenocytes (10 5 ) in the presence of 1 μg/mL NRP-A7
for 48 h. Culture supernatants were collected for IFN-γ determination by ELISA.
Analysis of Treg TCR-α and TCR-β Repertoire by PCR. CD4 + CD25 + Tregs and CD4 + CD25 -T-cells were isolated from splenocytes and PLN cells by FACS and used as a source of mRNA using the RNeasy minikit (Qiagen). cDNA was synthesized by oligo dT-primed reverse transcription using M-MLV RT (Invitrogen) followed by two rounds of PCR amplication using TCR-Cα or -Cβ and Vα-and Vβ-chain-specific primers, as previously described (29) .
In Vivo Treg Suppression Assay. CD4 + CD25 + Tregs (2 × 10 5 ) were injected intravenously into 5-6 wk-old NOD.scid females. At 24 h post-Treg infusion, the hosts were transfused with purified CD4
+ and CD8 + T-cells (2 × 10 7 ) isolated from the spleens of prediabetic 7-9-wk old NOD female mice. Mice were monitored weekly for development of glycosuria for at least 100 d.
Insulitis Scoring. Scoring of insulitic lesions was performed as previously described (38) .
